Artículos de revistas sobre el tema "FDA-approved drug"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "FDA-approved drug".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Gould, Stephen J. "AIDS and FDA Drug-Approved Policy:". Journal of Health & Social Policy 2, n.º 2 (21 de febrero de 1991): 39–46. http://dx.doi.org/10.1300/j045v02n02_03.
Texto completoVokinger, Kerstin Noëlle y Aaron S. Kesselheim. "Application of orphan drug designation to cancer treatments (2008–2017): a comprehensive and comparative analysis of the USA and EU". BMJ Open 9, n.º 10 (octubre de 2019): e028634. http://dx.doi.org/10.1136/bmjopen-2018-028634.
Texto completoZhong, Hao, Ging Chan, Yuanjia Hu, Hao Hu y Defang Ouyang. "A Comprehensive Map of FDA-Approved Pharmaceutical Products". Pharmaceutics 10, n.º 4 (6 de diciembre de 2018): 263. http://dx.doi.org/10.3390/pharmaceutics10040263.
Texto completoEzeife, Doreen Anuli, Patricia Tang, Daniel Yick Chin Heng y Stephen Welch. "Comparison of drug approval between health Canada (HC) and the U.S. Food and Drug Administration (FDA)." Journal of Clinical Oncology 30, n.º 15_suppl (20 de mayo de 2012): 6082. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.6082.
Texto completoSaberian, Nafiseh, Azam Peyvandipour, Michele Donato, Sahar Ansari y Sorin Draghici. "A new computational drug repurposing method using established disease–drug pair knowledge". Bioinformatics 35, n.º 19 (6 de marzo de 2019): 3672–78. http://dx.doi.org/10.1093/bioinformatics/btz156.
Texto completoHershman, Dawn L., Alfred I. Neugut, Donna Buono, Catherine A. Richards, Sherry A. Glied y Jason Dennis Wright. "Off-label and compendia use of chemotherapy in patients with metastatic cancer." Journal of Clinical Oncology 31, n.º 15_suppl (20 de mayo de 2013): 6509. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.6509.
Texto completoNair, Aathira Sujathan, Ashutosh Kumar Singh, Astik Kumar, Sunil Kumar, Sunitha Sukumaran, Vishal Payyalot Koyiparambath, Leena K. Pappachen, T. M. Rangarajan, Hoon Kim y Bijo Mathew. "FDA-Approved Trifluoromethyl Group-Containing Drugs: A Review of 20 Years". Processes 10, n.º 10 (11 de octubre de 2022): 2054. http://dx.doi.org/10.3390/pr10102054.
Texto completoKlasmeier, Coleen y Martin H. Redish. "Off-Label Prescription Advertising, the FDA and the First Amendment: A Study in the Values of Commercial Speech Protection". American Journal of Law & Medicine 37, n.º 2-3 (junio de 2011): 315–57. http://dx.doi.org/10.1177/009885881103700206.
Texto completoLosben, Nancy L. "2020: A Record Year for Drug Approvals". Senior Care Pharmacist 36, n.º 4 (1 de abril de 2021): 174–75. http://dx.doi.org/10.4140/tcp.n.2021.174.
Texto completoRizzo, Carla, Sara Amata, Ivana Pibiri, Andrea Pace, Silvestre Buscemi y Antonio Palumbo Piccionello. "FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022". International Journal of Molecular Sciences 24, n.º 9 (23 de abril de 2023): 7728. http://dx.doi.org/10.3390/ijms24097728.
Texto completoKim, Jeeyun A., Rachel Ceccarelli y Christine Y. Lu. "Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000–2020)". Journal of Personalized Medicine 11, n.º 3 (4 de marzo de 2021): 179. http://dx.doi.org/10.3390/jpm11030179.
Texto completoCeccoli, Stephen J. "Policy Punctuations and Regulatory Drug Review". Journal of Policy History 15, n.º 2 (abril de 2003): 157–91. http://dx.doi.org/10.1353/jph.2003.0011.
Texto completoGnanasakthy, Ari, Carla DeMuro, Marci Clark, Emily Haydysch, Esprit Ma y Vijayveer Bonthapally. "Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014)". Journal of Clinical Oncology 34, n.º 16 (1 de junio de 2016): 1928–34. http://dx.doi.org/10.1200/jco.2015.63.6480.
Texto completoChopra, S., M. Torres-Ortiz, L. Hokama, P. Madrid, M. Tanga, K. Mortelmans, K. Kodukula y A. K. Galande. "Repurposing FDA-approved drugs to combat drug-resistant Acinetobacter baumannii". Journal of Antimicrobial Chemotherapy 65, n.º 12 (22 de septiembre de 2010): 2598–601. http://dx.doi.org/10.1093/jac/dkq353.
Texto completoDesai, Bansri, Kyungwan Hong, John H. Powers y Peter Doshi. "Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling". Journal of General Internal Medicine 35, n.º 1 (28 de octubre de 2019): 377–79. http://dx.doi.org/10.1007/s11606-019-05460-2.
Texto completo&NA;. "New anti-Parkinsonian drug approved by US FDA". Inpharma Weekly &NA;, n.º 1095 (julio de 1997): 22. http://dx.doi.org/10.2165/00128413-199710950-00044.
Texto completoDeWitt, Sheila H. y Bruce E. Maryanoff. "Deuterated Drug Molecules: Focus on FDA-Approved Deutetrabenazine". Biochemistry 57, n.º 5 (21 de noviembre de 2017): 472–73. http://dx.doi.org/10.1021/acs.biochem.7b00765.
Texto completoWetzel, Carlie, Mitchell Lonneman y Chun Wu. "Polypharmacological drug actions of recently FDA approved antibiotics". European Journal of Medicinal Chemistry 209 (enero de 2021): 112931. http://dx.doi.org/10.1016/j.ejmech.2020.112931.
Texto completoDo, Michael, Bona Shin, Elaina Lioudis y Emaleigh Munn. "Novel Drugs Approved in 2021-2022". Transformative Medicine 1, n.º 3 (septiembre de 2022): 72–77. http://dx.doi.org/10.54299/tmed/zcno1399.
Texto completoRodwin, Marc A. "Rooting Out Institutional Corruption to Manage Inappropriate Off-Label Drug Use". Journal of Law, Medicine & Ethics 41, n.º 3 (2013): 654–64. http://dx.doi.org/10.1111/jlme.12075.
Texto completoOmae, Kenji, Yuki Kataoka, Yasushi Tsujimoto, Yusuke Tsutsumi, Shunichi Fukuhara y Toshi Furukawa. "Publication statuses of clinical trials supporting immune checkpoint inhibitors recently approved by the United States Food and Drug Administration: A meta-epidemiological investigation." Journal of Clinical Oncology 37, n.º 8_suppl (10 de marzo de 2019): 89. http://dx.doi.org/10.1200/jco.2019.37.8_suppl.89.
Texto completoHamrell, Michael R., Marilyn N. Martinez, Shrikant V. Dighe y Paul D. Parkman. "Bioequivalence of Generic Thioridazine Drug Products—The FDA Viewpoint". Drug Intelligence & Clinical Pharmacy 21, n.º 4 (abril de 1987): 362–69. http://dx.doi.org/10.1177/106002808702100413.
Texto completoGoodman, Aaron M., Michael Choi, Matthew Wieduwilt, Carolyn Mulroney, Caitlin Costello, Garrett Frampton, Vincent Miller y Razelle Kurzrock. "Next-Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients With Lymphoid Malignancies". JCO Precision Oncology, n.º 1 (noviembre de 2017): 1–13. http://dx.doi.org/10.1200/po.16.00004.
Texto completoReddy, D. Samba y Savitha Reddy. "The Novel Drugs of 2015 – An Extraordinary Growth of Innovative Pharmaceuticals". International Journal of Pharmaceutical Sciences and Nanotechnology 9, n.º 4 (31 de julio de 2016): 3331–36. http://dx.doi.org/10.37285/ijpsn.2016.9.4.1.
Texto completoMiller, Jennifer E., Marc Wilenzick, Nolan Ritcey, Joseph S. Ross y Michelle M. Mello. "Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies". BMJ Open 7, n.º 12 (diciembre de 2017): e017917. http://dx.doi.org/10.1136/bmjopen-2017-017917.
Texto completoLindstrom, Jill A. "Sources of drug information: FDA-approved labeling and other official FDA sources". Dermatologic Therapy 22, n.º 3 (mayo de 2009): 246–56. http://dx.doi.org/10.1111/j.1529-8019.2009.01238.x.
Texto completoMonge, Andrea N., Daniel W. Sigelman, Robert J. Temple y Harinder Singh Chahal. "Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021". JAMA Network Open 5, n.º 11 (1 de noviembre de 2022): e2239336. http://dx.doi.org/10.1001/jamanetworkopen.2022.39336.
Texto completoGonzalez, Misty L. "New Drug Review-Ezogabine (Potiga): Seizing the seizure". Mental Health Clinician 1, n.º 6 (1 de diciembre de 2011): 135–36. http://dx.doi.org/10.9740/mhc.n89803.
Texto completoSochacka-Ćwikła, Aleksandra, Marcin Mączyński y Andrzej Regiec. "FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review". Cancers 14, n.º 1 (24 de diciembre de 2021): 87. http://dx.doi.org/10.3390/cancers14010087.
Texto completoTaylor, Richard D., Malcolm MacCoss y Alastair D. G. Lawson. "Combining Molecular Scaffolds from FDA Approved Drugs: Application to Drug Discovery". Journal of Medicinal Chemistry 60, n.º 5 (23 de diciembre de 2016): 1638–47. http://dx.doi.org/10.1021/acs.jmedchem.6b01367.
Texto completoGable, Kelly N. "New Drug Review: Lurasidone (Latuda®) - The new antipsychotic on the block". Mental Health Clinician 1, n.º 6 (1 de diciembre de 2011): 131–32. http://dx.doi.org/10.9740/mhc.n89387.
Texto completoGable, Kelly N. "Saphris: Does a unique delivery system equal a unique drug?" Mental Health Clinician 1, n.º 6 (1 de diciembre de 2011): 133–34. http://dx.doi.org/10.9740/mhc.n89388.
Texto completoAl Shaer, Danah, Othman Al Musaimi, Fernando Albericio y Beatriz de la Torre. "2018 FDA Tides Harvest". Pharmaceuticals 12, n.º 2 (5 de abril de 2019): 52. http://dx.doi.org/10.3390/ph12020052.
Texto completoKumar Shukla, Ajay, Kumar Shukla, Rekha Mehani, Swati Jain y Sheema Maqsood. "Analysis of FDA Novel Drug Approvals". Biomedical and Pharmacology Journal 14, n.º 1 (28 de marzo de 2021): 225–33. http://dx.doi.org/10.13005/bpj/2117.
Texto completoHuey, Ryan, Seerat Anand, Jane Elizabeth Rogers, Arvind Dasari, Gauri Rajani Varadhachary, Anirudh Gothwal, Jonathan M. Loree, Lee M. Ellis, Michael J. Overman y Kanwal Pratap Singh Raghav. "Value appraisal of FDA approved cancer drugs over the past decade." Journal of Clinical Oncology 37, n.º 27_suppl (20 de septiembre de 2019): 115. http://dx.doi.org/10.1200/jco.2019.37.27_suppl.115.
Texto completoHuey, Ryan, Seerat Anand, Jane Rogers, Arvind Dasari, Gauri Rajani Varadhachary, Anirudh Gothwal, Jonathan M. Loree, Lee M. Ellis, Michael J. Overman y Kanwal Pratap Singh Raghav. "Value appraisal of FDA approved cancer drugs over the past decade." Journal of Clinical Oncology 37, n.º 15_suppl (20 de mayo de 2019): e18385-e18385. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e18385.
Texto completoHolmes, Jamie y Robin Hieber. "New Drug Review: Clobazam (Onfi®) - A “new” anticonvulsant option". Mental Health Clinician 1, n.º 6 (1 de diciembre de 2011): 126–27. http://dx.doi.org/10.9740/mhc.n89385.
Texto completoNewton, Uma y Tiffany-Jade Kreys. "Iloperidone (Fanapt®): Fan or not?" Mental Health Clinician 1, n.º 6 (1 de diciembre de 2011): 137–39. http://dx.doi.org/10.9740/mhc.n89390.
Texto completoWerremeyer, Amy B. "New Drug Review: Gabapentin enacarbil extended release (Horizant™) – A new formulation on the horizon". Mental Health Clinician 1, n.º 6 (1 de diciembre de 2011): 128–30. http://dx.doi.org/10.9740/mhc.n89391.
Texto completoGonzalez, Misty L. "Viibryd (Vilazodone): Viable option or for the byrds?" Mental Health Clinician 1, n.º 6 (1 de diciembre de 2011): 140–41. http://dx.doi.org/10.9740/mhc.n89810.
Texto completoChancey, Rebecca J., Yon Yu, Patricia Yu, Julian Jolly y Susan Montgomery. "770. Otherwise Unavailable Non-Malarial Parasitic Disease Treatment Drugs in the United States: an Update from CDC Parasitic Diseases Drug Service". Open Forum Infectious Diseases 7, Supplement_1 (1 de octubre de 2020): S429—S430. http://dx.doi.org/10.1093/ofid/ofaa439.960.
Texto completoAKERMI, SARRA, Neha Lohar, Subrata Sinha, Surabhi Johari, Sunil Jayant y Anshul Nigam. "In-silico identification of natural antiviral drug against SARS-CoV-2 and comparison with potential FDA approved drug targets". Journal of Science 3, n.º 4 (5 de septiembre de 2020): 1–11. http://dx.doi.org/10.47944/jos.3.4.2020.1.
Texto completoVokinger, Kerstin Noëlle, Paola Daniore, Thomas J. Hwang, ChangWon C. Lee y Aaron S. Kesselheim. "Pivotal trial endpoints and prices of cancer drugs in the US and Europe." Journal of Clinical Oncology 38, n.º 15_suppl (20 de mayo de 2020): 2077. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.2077.
Texto completoShabir, Ghulam, Aamer Saeed, Wajeeha Zahid, Fatima Naseer, Zainab Riaz, Nafeesa Khalil, Muneeba y Fernando Albericio. "Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016–2022)". Pharmaceuticals 16, n.º 8 (15 de agosto de 2023): 1162. http://dx.doi.org/10.3390/ph16081162.
Texto completoBeinse, Guillaume, Virgile Tellier, Valentin Charvet, Eric Deutsch, Isabelle Borget, Christophe Massard, Antoine Hollebecque y Loic Verlingue. "Prediction of Drug Approval After Phase I Clinical Trials in Oncology: RESOLVED2". JCO Clinical Cancer Informatics, n.º 3 (diciembre de 2019): 1–10. http://dx.doi.org/10.1200/cci.19.00023.
Texto completoKhaki, Ali Raza, Aakash Desai, Martin W. Schoen, Bishal Gyawali, Eddy J. Chen, Peter C. Yang y Jeremy Lyle Warner. "Timing of US Food and Drug Administration (FDA) cancer drug approvals relative to publication of clinical trial results." Journal of Clinical Oncology 38, n.º 15_suppl (20 de mayo de 2020): 2071. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.2071.
Texto completoChen, Charles H. y Timothy K. Lu. "Development and Challenges of Antimicrobial Peptides for Therapeutic Applications". Antibiotics 9, n.º 1 (13 de enero de 2020): 24. http://dx.doi.org/10.3390/antibiotics9010024.
Texto completoReddy, Neha K., Jason Roszik, David Carl Norris, Roman Groisberg, Niamh Coleman, Omar Alhalabi, Ethan B. Ludmir, Cullen M. Taniguchi, Ishwaria Mohan Subbiah y Vivek Subbiah. "Dosing, drug reduction, drug interruption, and drug discontinuation rates among U.S. FDA approved tyrosine kinase inhibitors." Journal of Clinical Oncology 39, n.º 15_suppl (20 de mayo de 2021): 3112. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.3112.
Texto completoRodriguez-Monguio, Rosa, Enrique Seoane-Vazquez y John H. Powers. "A Comparative Assessment of Approvals and Discontinuations of Systemic Antibiotics and Other Therapeutic Areas". Healthcare 11, n.º 12 (15 de junio de 2023): 1759. http://dx.doi.org/10.3390/healthcare11121759.
Texto completoVadola, Lisa Ambrosini, Monique A. Pond, Ann Winter-Vann y Robin Whitsell. "Faster approvals?: Trends in the use of FDA’s expedited approval programs for oncology medications." Journal of Clinical Oncology 35, n.º 15_suppl (20 de mayo de 2017): e18270-e18270. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e18270.
Texto completo